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Introduction
============

Atherosclerotic cerebral infarction (ACI) is an important type of ischemic stroke and is also an important cause of mortality and disability in China^[@bib1])^. Atherosclerosis (AS) is the fundamental pathogenesis for ACI and many other ischemic cardio-cerebrovascular diseases, including coronary heart disease and thromboembolic disease^[@bib2])^. Though there are many theories concerning the process of AS^[@bib3]--[@bib5])^, thus far, the pathogenesis of AS has not been fully addressed because of a complex etiology involving genetic and environmental contributions; therefore, limited effective prevention and control by drugs have been used to treat the AS-related diseases, particularly ACI.

According to the most accepted inflammation--injury--reaction theory, AS is a chronic inflammatory disease caused by multiple etiological factors. Endothelial damage caused by oxidized-low density lipoprotein (ox-LDL) is involved in the early stage of AS^[@bib6]--[@bib8])^. Currently, many ox-LDL receptors have been found and identified on the AS-related cells, such as endothelial cells, vascular smooth muscle cells (VSMCs), monocytes, macrophages, and foam cells^[@bib9],\ [@bib10])^. Most of the receptors belong to scavenger receptor family, and their interactions with ox-LDL may display a crucial role in the process of AS. However, subsequent studies have demonstrated that the expression of these receptors in endothelial cells is very low, therefore, the actual role of the scavenger receptors in AS was limited.

The molecular mechanism underlying the activation, dysfunction, and damage of endothelia cells was not fully elucidated until the discovery of lectin-like oxidized LDL receptor-1 (LOX-1) in the 20th century. LOX-1 was reported for the first time by Sawamura et al in bovine aortic endothelial cells which consisted of 270 amino acid residues with a relative molecular weight at 30872^[@bib11])^. Human LOX-1 is a type II single transmembrane protein which belongs to type C selectin family, but the structure and sequence of LOX-1 is different from any known scavenger receptors. LOX-1 is composed of four protein domains: N terminal cytoplasmic, transmembrane, link, and C-terminal lectin-like domain^[@bib12])^. The LOX 1 gene is a single copy gene with 19 kb nucleotides and eight exons. Emerging evidence has demonstrated that LOX-1 mainly expresses on AS-related cells (endothelia cells, VSMCs, and monocytes) and exhibits high ligand specificity to ox-LDL (every three LOX-1 receptors combined with an ox-LDL)^[@bib13])^.

Accumulated studies have proved the association of LOX-1 with AS in both *in vitro* and *in vivo* experiments. Vascular endothelial dysfunction is the initiating factor for AS. After activation by its ligand ox-LDL, LOX-1 can induce the damage of endothelial cells, promote adhesion of monocytes, trigger the apoptotic mechanism of endothelial cells, and finally lead to the formation and development of AS^[@bib14],\ [@bib15])^. Activated LOX-1 also functions as an inducer of reactive oxygen species (ROS) in endothelia cells by stimulating NADPH oxidase and mitochondrial electron transport chain pathways^[@bib16])^. The produced ROS can directly interact with nitric oxide (NO) and result in increased levels of peroxinitrites which subsequently inactivate NO and induce the dysfunction of the endothelium. VSMCs play an important role in regulating the vasomotor function of vessels; proliferation and migration of VSMCs are also involved in the pathogenesis of AS in early stages. Elevated levels of ox-LDL could induce LOX-1 expression in VSMCs, particularly in atherosclerotic plaques, by activating ERK, p38MAPK, and PI3K pathways^[@bib17],\ [@bib18])^. Furthermore, some studies confirmed that the adhesion capacity of monocytes was mediated by LOX-1 in the process of AS^[@bib19])^.

Though the role of LOX-1 in AS has been regarded as a research focus in recent years, there are limited studies concerning the association of certain single nucleotide polymorphism (SNP) in the LOX-1 gene with the susceptibility to ACI. Therefore, here we conducted a case-controlled study to explore the possible role of a functional SNP rs1050283 present in the 3′-untranslated region (3′-UTR) of the LOX-1gene in ACI. Moreover, LOX-1 can be hydrolysed and released into the blood by specific proteases; the hydrolysis product, known as sLOX-1, was recently reported to be a potential biomarker for cardiovascular diseases^[@bib20])^. Therefore, we also analyzed the association of the rs1050283 polymorphism with serum levels of sLOX-1 to identify the feasibility of using the rs1050283 polymorphism as a new predictor for ACI.

Methods
=======

Subjects
--------

The present study included 526 patients diagnosed with ACI and 640 healthy controls from unrelated Chinese Han population in the Hunan Province of China. The patients were hospitalized in the Department of Neurology, the Third Xiangya Hospital of Central South University between July 2012 and December 2015. All patients with ACI were confirmed by brain CT and/or MRI with clinical neurological examination, and macroangiopathy was defined by transcranial doppler ultrasonography (TCD), carotid color ultrasonography, and head magnetic resonance angiography (MRA). The healthy controls were recruited from the health management center of the Third Xiangya Hospital, matched by sex and age, and without a history of hypertension, diabetes mellitus, and clinical or radiological evidence of stroke and other neurological diseases. Five-milliliter venous blood sample was drawn into ethylenediaminetetraacetic acid-containing tubes. Plasma and peripheral leukocytes were isolated immediately and separately stored at −20°C until analysis. Serum levels of alanine transaminase (ALT), aspartate transaminase (AST), total cholesterol (TC), triglyceride (TG), high-density lipoprotein (HDL), LDL, creatinine (Cr), and sLOX-1 were measured in all participants. Detailed personal information (age, gender, body mass index, and history of hypertension and diabetes) of all patients and controls were collected using a structured questionnaire.

Written informed consent was obtained from all participants. The study was approved by the ethical committee of the Third Xiangya Hospital of Central South University.

Genotyping
----------

Genomic DNA samples were extracted from whole blood samples using a DNA Purification Kit (Promega, Madison, USA). The LOX-1 rs1050283 polymorphism was genotyped by DNA sequencing method completed by Sangon Biological Company. For genotyping, the following primers for PCR amplification were designed by Primer Premier 5.0: 5′-ATT TGAAGGCTCTGGAAG-3′ (sense) and 5′-TTCTTG ATTTCGGAATGG-3′ (antisense). PCR reaction was performed in a final volume of 20 *µ*l, containing 10 *µ*l of 2 × PCR buffer, 1 *µ*l of each primer (10 pmol), 2 *µ*l of the genomic DNA template, and 6 *µ*l of ddH~2~O. The PCR amplification condition is described as follow: a denaturation step at 95°C for 5 min, followed by 37 cycles of denaturation at 95°C for 30 s, annealing at 60°C for 45 s, extension at 72°C for 30 s, and a final incubation at 72°C for 10 min.

Isolation of Peripheral Blood Mononuclear Cells (PBMCs) from Patients with ACI and Controls
-------------------------------------------------------------------------------------------

PBMCs were collected from the whole blood samples of patients with ACI and healthy controls. After centrifugation at 2000 g for 30 min upon 5 ml Ficoll-Hypaque gradients (Sigma, USA), the monocytes from the buffy coat were extracted and washed twice with ice cold PBS before suspending in RPMI 1640 containing 10% fetal calf serum (FCS). Then the cells were cultured in a 5% CO~2~ incubator at 37°C^[@bib21])^.

Real-Time PCR Analysis
----------------------

To assess differential LOX-1 mRNA expression in PBMCs from patients with ACI and healthy controls, real-time PCR was performed according to manufacturer\'s instructions using ABI 7500 real-time PCR system using SYBR Green method. Sequences of primers were as follows: LOX-1: 5′-CTGATGACTCC TCCCCAGAA-3′(sense) and 5′-CGAGCATCAAGA TGGAGACA-3′(antisense) and GAPDH (endogenous control): 5′-CTGC ACCA CCAACTGCTTAG-3′(sense) and 5′-AGGTC CACCACTGACACGTT-3′(antisense). Relative LOX-1 mRNA expression was normalized to the expression level of GAPDH. All amplification reactions were performed in triplicate.

Western Blot
------------

Protein was extracted from PBMCs in six-well culture-plates with RIPA lysis buffer (Beyotime Biotech, China). The BCA protein quantitation kit was used to determine the protein content of each sample. An equal amount of 10 µg total protein was separated on SDS-polyacrylamide gel electrophoresis(SDS-PAGE) (Beyotime Biotech, China) and then transferred onto polyvinylidene fluoride (PVDF) membranes (EMD Millipore, Billerica, MA, USA). The PVDF membranes were incubated in blocking solution (5% non-fat milk) for 1 h at room temperature and then incubated in LOX-1 (Abcam, UK) or GAPDH (Abcam, UK) primary antibody overnight at 4°C followed by the addition of horseradish peroxidase-conjugated secondary antibody. The immunoblots were detected using an enhanced chemiluminescence system (ChemiDoc XRS; Bio-Rad, USA), and the relative intensities were analyzed using a Bio-Rad Calibrated Densitometer. We used the following method to compare results in different membranes: when Western blotting was completed, a sample from this Western blot was selected to perform the next Western blotting with other samples. Once Western blotting of all samples was completed, data was homogenized according to the chosen sample.

Determination of Serum Levels of sLOX-1
---------------------------------------

Serum levels of sLOX-1 were measured using a sLOX-1 ELISA Kit (R&D Systems, USA). The intra and inter-assay coefficients of variation were 4% and 5%, respectively.

Statistical Analysis
--------------------

Statistical analysis was performed using the software SSPS 16.0. Frequencies of the genotypes and alleles of the LOX-1 polymorphism were evaluated using the *χ*^2^ test. Differences among the groups were compared using the one-way ANOVA test. Descriptive results of continuous variables were expressed as mean ± SD. A *P* value \< 0.05 was considered significant.

Results
=======

Clinical and Laboratory Characteristics of Patients with ACI and Healthy Controls
---------------------------------------------------------------------------------

The distribution of clinical and risk factors are summarized in **[Table 1](#T1){ref-type="table"}**. Patients with ACI showed increased levels of systolic blood pressure, diastolic blood pressure, and serum LDL and lower levels of HDL. Patients with ACI also showed a higher prevalence of smoking. No differences were found between patients with ACI and healthy controls with respect to gender, age, and other indexes.

###### Clinical characteristics of the ACI patients and healthy controls

  Characteristics                               ACI             Controls        *P*
  --------------------------------------------- --------------- --------------- ----------
  Gender (male/female)                          299/227         332/308         NS
  Age (years)                                   63.16 ± 8.27    62.58 ± 7.82    NS
  BMI (kg/m^2^)                                 24.21 ± 1.89    23.26 ± 2.12    NS
  SBP (mmHg)                                    132 ± 18        118 ± 15        \< 0.001
  DBP (mmHg)                                    81 ± 12         75 ± 8          \< 0.001
  Cr (mmol/L)                                   88.54 ± 15.41   87.92 ± 13.42   NS
  HDL-C (mmol/L)                                1.13 ± 0.43     1.49 ± 0.29     \< 0.001
  LDL-C (mmol/L)                                2.88 ± 0.63     2.06 ± 0.64     \< 0.001
  TG (mmol/L)                                   1.75 ± 1.02     1.72 ± 0.82     NS
  TC (mmol/L)                                   4.46 ± 0.72     4.41 ± 0.85     NS
  Hypertension (%)                              318 (60.46)     0 (0)           \< 0.001
  Positive history of smoking (%)               240 (45.63)     179 (27.97)     \< 0.001
  Positive history of alcohol consumption (%)   147 (27.95)     165 (25.78)     NS
  Dia betes mellitus (%)                        102 (19.39)     0               \< 0.001

The rs1050283 Genotyping
------------------------

The rs1050283 polymorphism of LOX-1 was genotyped by the sequencing method. As shown in **[Fig. 1](#F1){ref-type="fig"}**, three genotypes (TT, CT, and CC) were identified in this study.

![DNA sequencing diagram of the LOX-1 rs1050283 polymorphism\
(A) TT genotype, (B) CT genotype, and (C) CC genotype.](jat-24-572-g001){#F1}

Association of the rs1050283 Polymorphism with Risk for ACI
-----------------------------------------------------------

The distribution of genotypes was consistent with the Hardy--Weinberg equilibrium in patients with ACI and healthy controls. As shown in **[Table 2](#T2){ref-type="table"}**, the LOX-1 rs1050283 TT genotype was overrepresented in patients with ACI compared with the healthy controls (10.8% vs 7.0%, *χ*^2^ = 10.51, *P* \< 0.01). The comparison of the genotype distribution between patients with ACI and healthy controls also demonstrated that the frequency of the rs1050283 T allele in patients with ACI was significantly higher than that in healthy controls (28.3% vs 22.1%, *χ*^2^ = 11.93, *P* \< 0.01, OR = 1.39, 95% CI: 1.15--1.68).

###### Genotype distribution and allele frequency of LOX-1 rs1050283 polymorphism in ACI patients and healthy controls

                 *n*   Genotype(%)   Allele(%)                                       
  -------------- ----- ------------- ------------ ------------ --------------------- ------------
  ACI patients   526   57 (10.8)     184 (35.0)   285 (54.2)   298 (28.3)            754 (71.7)
  Controls       640   45 (7.0)      193 (30.2)   402 (62.8)   283 (22.1)            997 (77.9)
  *χ*^2^                             10.507                    11.933                
  *P*-value                          0.005                     0.001                 
  OR (95%CI)                                                   1.392 (1.154∼1.681)   

The Difference of LOX-1 Expression between Patients with ACI and Healthy Controls
---------------------------------------------------------------------------------

Given the important role of LOX-1 expression in the process of AS, we extracted PBMCs from 120 patients with ACI and 120 healthy controls randomly to determine the LOX-1 expression (the background data of these subjects are listed in **[Table 3](#T3){ref-type="table"}**). In our study, increased LOX-1 expression at the mRNA and protein levels was observed in patients with patients with ACI compared with that in healthy controls (**[Fig. 2A](#F2){ref-type="fig"}** and **[Fig. 2B](#F2){ref-type="fig"}**), which pointed to an enhanced function of LOX-1 in patients with ACI. Our findings were in line with those of the previous reports that increased levels of LOX-1 were associated with AS-related diseases.

###### Clinical characteristics of the ACI patients and healthy controls (*n* = 120, respectively)

  Characteristics                               ACI             Controls        *P*
  --------------------------------------------- --------------- --------------- ----------
  Gender (male/female)                          72/48           68/52           NS
  Age (years)                                   62.84 ± 7.69    62.41 ± 7.25    NS
  BMI (kg/m^2^)                                 24.21 ± 1.89    23.26 ± 2.12    NS
  SBP (mmHg)                                    128 ± 16        120 ± 14        \< 0.05
  DBP (mmHg)                                    78 ± 15         74 ± 10         \< 0.05
  Cr (mmol/L)                                   90.68 ± 13.46   89.35 ± 12.67   NS
  HDL-C (mmol/L)                                1.15 ± 0.38     1.52 ± 0.42     \< 0.001
  LDL-C (mmol/L)                                2.85 ± 0.56     2.05 ± 0.62     \< 0.001
  TG (mmol/L)                                   1.76 ± 1.13     1.75 ± 0.91     NS
  TC (mmol/L)                                   4.38 ± 0.85     4.45 ± 0.81     NS
  Hypertension (%)                              75 (62.5)       0 (0)           \< 0.001
  Positive history of smoking (%)               50 (41.67)      38 (31.67)      \< 0.001
  Positive history of alcohol consumption (%)   32 (26.67)      34 (28.33)      NS
  Diabetes mellitus (%)                         25 (20.83)      0               \< 0.001

![The difference in LOX-1 expression between patients with ACI and healthy controls\
(A) LOX-1 mRNA expression in patients with ACI and healthy controls. Data are expressed as mean ± SD, *n* = 120 in each group. LOX-1 mRNA expression in PBMCs was determined by real-time PCR and expressed as ratio of the control. \*\**P* \< 0.01 vs. healthy controls. (B) LOX-1 protein expression in patients with ACI and healthy controls. Data are expressed as mean ± SD, *n* = 120 in each group. LOX-1 protein expression in PBMCs was measured by Western blot and expressed as ratio of the control. \*\**P* \< 0.01 vs. healthy controls. ACI: atherosclerotic cerebral infarction patients and controls: healthy controls.](jat-24-572-g002){#F2}

The Effect of the rs1050283 Polymorphism on LOX-1 Expression
------------------------------------------------------------

Here we also tried to explore whether the rs1050283 polymorphism affected the LOX-1 expression in PBMCs. We used real-time PCR and Western blot to measure the LOX-1 expression from 135 randomly selected patients with ACI (*n* = 45 in each genotype group; the background data of these subjects are listed in **[Table 4](#T4){ref-type="table"}**). Our results demonstrated that among patients with ACI, carriers of the rs1050283 T allele showed higher LOX-1 expression at the mRNA and protein levels (**[Fig. 3A](#F3){ref-type="fig"}** and **[Fig. 3B](#F3){ref-type="fig"}**). However, we failed to observe an apparent association of LOX-1 rs1050283 polymorphism with LOX-1 expression in healthy controls (data not shown). Therefore, these results indicated that the rs1050283 polymorphism might be associated with impaired post-transcription modification of LOX-1 and the process and severity of ACI; patients with ACI carried the rs1050283 T allele might show a more severe status of disease because of the higher LOX-1 expression.

###### Clinical characteristics of the subjects from 3 genotype groups in ACI patients (*n* = 45, respectively)

  Characteristics                               TT              CT              CC              *P*
  --------------------------------------------- --------------- --------------- --------------- -----
  Gender (male/female)                          24/21           26/19           22/23           NS
  Age (years)                                   62.18 ± 6.54    64.16 ± 5.89    63.28 ± 7.64    NS
  BMI (kg/m^2^)                                 23.72 ± 1.69    24.15 ± 1.47    24.55 ± 2.33    NS
  SBP (mmHg)                                    136 ± 12        126 ± 16        130 ± 9         NS
  DBP (mmHg)                                    84 ± 17         79 ± 14         82 ± 10         NS
  Cr (mmol/L)                                   84.31 ± 11.59   89.43 ± 15.87   91.20 ± 17.24   NS
  HDL-C (mmol/L)                                1.12 ± 0.44     1.21 ± 0.52     1.15 ± 0.39     NS
  LDL-C (mmol/L)                                2.76 ± 0.48     2.92 ± 0.57     2.84 ± 0.62     NS
  TG (mmol/L)                                   1.78 ± 1.02     1.68 ± 1.22     1.73 ± 0.95     NS
  TC (mmol/L)                                   4.36 ± 0.74     4.42 ± 0.88     4.27 ± 0.62     NS
  Hypertension (%)                              26 (57.78)      28 (62.22)      25 (55.56)      NS
  Positive history of smoking (%)               21 (46.67)      20 (44.44)      22 (48.89)      NS
  Positive history of alcohol consumption (%)   12 (26.67)      14 (31.11)      12 (26.67)      NS
  Diabetes mellitus (%)                         8 (17.78)       11 (24.44)      10 (22.22)      NS

![Effects of the LOX-1 rs1050283 polymorphism on LOX-1 expression in patients with ACI\
(A) The difference in LOX-1 mRNA expression between different genotypes. Data are expressed as mean ± SD, *n* = 45 in each group. LOX-1 mRNA expression in PBMCs was determined by real-time PCR and expressed as ratio of the control. \*\**P* \< 0.01 vs. CC genotype group. (B) The difference of LOX-1 protein expression between different genotypes. Data are expressed as mean ± SD, *n* = 45 in each group. LOX-1 protein expression in PBMCs was measured by Western blot and expressed as ratio of the control. \*\**P* \< 0.01 vs. CC genotype group. TT: TT genotype, CT: CT genotype, and CC: CC genotype.](jat-24-572-g003){#F3}

The Effect of the rs1050283 Polymorphism on Serum Levels of sLOX-1
------------------------------------------------------------------

Previous studies have reported the possibility to regard sLOX-1 as a predictor of cardiovascular diseases. Therefore, here we examined the effect of the LOX-1 rs1050283 polymorphism on serum levels of sLOX-1. We first randomly selected 240 patients with ACI and 240 healthy controls to detect serum levels of sLOX-1 (the background data of these subjects are listed in **[Table 5](#T5){ref-type="table"}**). We found that the patients with ACI displayed a higher level of sLOX-1 than healthy controls. Moreover, the LOX-1 rs1050283 T allele was associated with increased serum levels of sLOX-1 in patients with ACI (**[Fig. 4A](#F4){ref-type="fig"}** and **[Fig. 4B](#F4){ref-type="fig"}**, *n* = 45 in each genotype group; the background data of these subjects are listed in **[Table 4](#T4){ref-type="table"}**), which suggested the potential role of the rs1050283 polymorphism as a new predictor for cardiovascular diseases.

###### Clinical characteristics of the ACI patients and healthy controls (*n* = 240, respectively)

  Characteristics                               ACI             Controls        *P*
  --------------------------------------------- --------------- --------------- ----------
  Gender (male/female)                          128/112         123/117         NS
  Age (years)                                   64.32 ± 9.66    63.39 ± 8.57    NS
  BMI (kg/m^2^)                                 23.74. ± 1.75   23.18 ± 2.06    NS
  SBP (mmHg)                                    128 ± 15        116 ± 12        \< 0.001
  DBP (mmHg)                                    78 ± 14         73 ± 10         \< 0.05
  Cr (mmol/L)                                   92.63 ± 16.56   89.47 ± 14.35   NS
  HDL-C (mmol/L)                                1.18 ± 0.36     1.45 ± 0.49     \< 0.001
  LDL-C (mmol/L)                                2.74 ± 0.52     1.88 ± 0.72     \< 0.001
  TG (mmol/L)                                   1.72 ± 0.82     1.74 ± 0.71     NS
  TC (mmol/L)                                   4.23 ± 0.85     4.28 ± 0.64     NS
  Hypertension (%)                              148 (61.67)     0 (0)           \< 0.001
  Positive history of smoking (%)               103 (42.92)     59 (24.58)      \< 0.001
  Positive history of alcohol consumption (%)   58 (24.17)      62 (25.83)      NS
  Diabetes mellitus (%)                         53 (22.08)      0               \< 0.001

![Serum levels of sLOX-1 in different groups (A) The difference in levels of sLOX-1 between patients with ACI and healthy controls. Data are expressed as mean ± SD, *n* = 240 in each group. Serum levels of sLOX-1 were assessed using ELISA. \*\**P* \< 0.01 vs. healthy controls. (B) The effect of the LOX-1 rs1050283 polymorphism on sLOX-1 in patients with ACI. Data are expressed as mean ± SD, *n* = 45 in each genotype group. \*\**P* \< 0.01 vs. CC genotype group. TT: TT genotype, CT: CT genotype, and CC: CC genotype.](jat-24-572-g004){#F4}

Discussion
==========

LOX-1 is a multiple ligand receptor that can interact with ox-LDL, advanced glycosylation end products, activated platelets, neutrophils, apoptotic/aging cells, C-reactive protein, and bacteria^[@bib22]--[@bib26])^. In addition to expression on endothelial cells, LOX-1 is also expressed on other cells, such as VSMCs, fibroblasts, myocardial cells, and macrophages. LOX-1 mediated signaling has been implicated in the development and progression of cardiovascular diseases^[@bib14],\ [@bib27])^. By interacting with ox-LOX-1, LOX-1 acts as a key regulator in activating endothelial cells, promoting the adhesion ability of monocytes to the endothelium, and altering VSMCs phenotype by increasing the levels of inflammatory chemokines and adhesion molecules, including monocyte chemotactic protein 1 (MCP-1), E-selectin, P-selectin, and vascular cell adhesion molecule-1 (VCAM-1)^[@bib28]--[@bib30])^. In ApoE knockout mice, pretreatment with an anti-LOX-1 antibody partly recovered the endothelial-dependent diastolic dysfunction of the micro coronary artery induced by high-fat diet^[@bib31],\ [@bib32])^. Using immunohistochemical and real-time PCR methods, Neri Serneri et al observed a higher LOX-1 expression in myocardial biopsy specimens from unstable angina patients than from stable angina patients. Furthermore, the exaggerated amount of myocardial ox-LDL and LOX-1 in unstable patients was associated with widespread high grade microvessel inflammation^[@bib33])^.

Emerging studies recently focused on the role of the LOX-1 gene polymorphism in cardiovascular diseases. Liu X reported that the G501C polymorphism, not the 3′-UTR-C188T polymorphism, was associated with the susceptibility to cerebral infarction in the northern Chinese Han population^[@bib34])^. Man BL, et al. reported that there was a significant association of the TT allele with concurrent stenoses of the extracranial and intracranial vessels in stroke patients^[@bib35])^. The IVS4-14 A \> G OLR1 polymorphism was also identified to be related to glucose metabolism disturbance, elevated levels of insulin, and lipid peroxidation in patients with metabolic syndrome, and individuals with GG genotype seemed to be more sensitive to these factors^[@bib36])^. There are also some studies that reported the role of the rs1050283 polymorphism in coronary artery disease and myocardial infarction^[@bib37]--[@bib40])^. However, thus far, no research has reported the association of the LOX-1 rs1050283 polymorphism with the susceptibility to ACI. AS mainly depends on the stenosis degree of the vessels and the ischemia degree of affected organs. Although AS is common basis for ACI and coronary artery disease, the brain and heart are two distinct organs with different blood and collateral circulations. Therefore, although the patients carried the same genotype of LOX-1, they may express different AS-associated diseases. Hence, we think that it is worthwhile to explore the association of the LOX-1 rs1050283 polymorphism with ACI, though some studies have reported the relationship between this polymorphism and coronary artery disease. In this study, we first observed the distribution of the rs1050283 T allele in patients with ACI and healthy controls to investigate whether the T allele can be regarded as an independent risk factor for ACI. Our results showed that the frequency of the rs1050283 T allele was significantly higher in patients with ACI than in healthy controls, and the 95% CI was 1.15--1.68, which suggested a high correlativity between the T allele and susceptibility to ACI. Because the rs1050283 T allele was closely related to ACI, we then asked how this polymorphism affects the process of ACI. A study recently published by Morini E demonstrated that the rs1050286 polymorphism of the LOX-1 gene is involved in the altered LOX-1 expression via modifying miR-24 binding in Hela cells^[@bib41])^. Therefore, in our study, we extracted the mRNA and protein in PBMCs from the recruited volunteers to test the effects of the rs1050283 polymorphism performed on LOX-1 expression in humans. Consistent with our expectations, carriers of the rs1050283 T allele were associated with increased LOX-1 expression at the mRNA and protein levels. Our results indicated that the rs1050283 polymorphism may impact certain miRNAs binding affinity to the 3′-UTR of LOX-1, causing impaired post-transcriptional modification in the presence of the T allele. Using bioinformatics, we found that the binding sites of some miRNAs, including miR-18a, miR-18b, miR-590-3p, and miR-1271, were close to the nucleotide sequences of the rs1050283 polymorphism; therefore, the abnormal expressions of these miRNAs may affect the process of ACI by targeting LOX-1. Hen ce, the disease process of ACI may cause different expressions of some miRNAs and then induce a different LOX-1 expression among the three genotypes because of different affinities in patients with ACI. Further research to determine whether the interaction between these miRNAs and LOX-1 can be influenced by the rs1050283 polymorphism is a clear demonstration of the ongoing need for detailed mechanistic understanding of the rs1050283 polymorphism.

Elevated serum levels of sLOX-1 have been observed in patients with acute coronary syndrome and cerebral infarction^[@bib42]--[@bib44])^. Circulating sLOX-1 was also reported to be a more sensitive and specific biomarker for acute coronary syndrome and ST elevation myocardial infarction than troponin T and heart-type fatty acid binding protein and provided additional diagnostic values when measured in combination with other laboratory indexes^[@bib20],\ [@bib45],\ [@bib46])^. As a hydrolysis product of LOX-1, it is of considerable relevance that serum levels of sLOX-1 could be influenced by the rs1050283 polymorphism because we have already identified a definite relationship between this polymorphism and LOX-1 expression. In line with previous studies, data from our research demonstrated that the serum level of sLOX-1 was significantly higher in patients with ACI than in healthy controls. We further explored the effect of the rs1050283 polymorphism on serum levels of sLOX-1 in patients with ACI. Some studies have reported the association of the rs1050283 polymorphism with serum levels of sLOX-1 in patients with coronary artery disease, myocardial infarction, Alzheimer\'s disease, and preeclampsia and healthy old people^[@bib38],\ [@bib47]--[@bib50])^. However, there was no research focused on the association of the rs1050283 polymorphism with serum levels of sLOX-1 in patients with ACI, and data concerning the association of this polymorphism with sLOX-1 seem conflicting. Brinkley TE et al reported that individuals with the CC genotype showed increased levels of sLOX-1^[@bib48])^, whereas other scientists suggested that the T allele of the rs1050283 polymorphism was associated with increased levels of sLOX-1^[@bib38],\ [@bib49],\ [@bib50])^. Therefore, we think that it is necessary for us to investigate the association among the rs1050283 polymorphism, LOX-1 expression, and serum levels of sLOX-1 in patients with ACI. In this study, we found that the rs1050283 T allele was associated with higher serum levels of sLOX-1 in patients with ACI, which suggested that the rs1050283 polymorphism may be used as a judgment index for the severity of ACI. Our results would provide supplementary evidence to current research about the role of the LOX-1 rs1050283 polymorphism in diseases.

Therefore, in our study, we investigated the effects of rs1050283 polymorphism on ACI susceptibility and sLOX-1 in Chinese people. We found that the rs1050283 T allele was associated with ACI susceptibility and increased serum levels of sLOX-1 in patients with ACI. Our data highlight the rs1050283 T allele as a novel risk factor for ACI. However, the exact mechanism by which the rs1050283 polymorphism exerts its function remains uncertain. Further studies regarding the role of this gene polymorphism in the cell signaling pathway in AS-related diseases are needed. The sample size of the patients with ACI in our study was limited; further large-scale and multicenter trials are also required to fully unveil the role of the LOX-1 rs1050283 polymorphism in ACI. Prospectively, targeting certain functional SNP in the LOX-1 gene could represent a promising therapeutic approach to attenuate the process of ACI induced by increased serum levels of ox-LDL.
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